Floatz logo

(+)-VINCRISTINE

Head and Neck Cancer

Taiho Pharmaceutical Co., Ltd.Small moleculePhase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

113 Active assets in the Head and Neck Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
ImmunityBio, Inc.
Phase 3BB
Carboplatin
Rapa Therapeutics LLC
Phase 3BB
Cyclophosphamide
Zelluna Immunotherapy AS
Phase 3BB
Epirubicin
Thomas Jefferson University
Phase 3BB
Pembrolizumab
Thomas Jefferson University
Phase 3BB

View all 50 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →